Shares of Ocular Therapeutix Inc. (NASDAQ:OCUL) reached a new 52-week low during trading on Tuesday . The company traded as low as $4.11 and last traded at $4.13, with a volume of 152,446 shares changing hands. The stock had previously closed at $4.38.

A number of analysts have commented on OCUL shares. BTIG Research reaffirmed a “buy” rating and set a $18.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, July 26th. Morgan Stanley reaffirmed an “overweight” rating and set a $16.00 price objective (down from $17.00) on shares of Ocular Therapeutix in a research note on Tuesday, June 7th. Zacks Investment Research lowered shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Cowen and Company reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research note on Monday, June 6th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $48.00 price target on shares of Ocular Therapeutix in a research report on Sunday, April 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $27.45.

The firm’s market cap is $104.02 million. The firm’s 50-day moving average is $5.04 and its 200 day moving average is $8.24.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.01. The business had revenue of $458 million for the quarter. On average, equities research analysts expect that Ocular Therapeutix Inc. will post ($1.86) EPS for the current year.

In related news, CEO Amarpreet Sawhney bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 9th. The shares were bought at an average cost of $6.70 per share, with a total value of $67,000.00. Following the acquisition, the chief executive officer now owns 573,733 shares in the company, valued at $3,844,011.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.